#MNPR

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 Monopar (Nasdaq: MNPR) presented new Phase 2 ALXN1840-WD-204 data at AASLD The Liver Meeting® 2025 on Nov 9, 2025 showing that ALXN1840 (tiomolybdate choline) produced a rapid, sustained improvement in daily copper balance in Wilson disease patients, driven primarily by increased fecal copper excretion.The study cohort (n=8) showed a mean daily copper balance that was significantly lower vs pre-treatment baseline. Improvement occurred during the initial 15 mg once-daily dosing period (days 1–28) and across the full treatment window (days 1–39), which included 15 mg every other day or 30 mg once-daily dosing. Presentation materials and the abstract are available online.

4 months ago

#MNPR Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

www.stocktitan.net/news/MNPR/monopar-presen...

0 0 0 0

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 Monopar Therapeutics (Nasdaq: MNPR) announced its abstract from the Phase 2 ALXN1840-WD-204 copper balance study was accepted for an oral presentation at AASLD – The Liver Meeting® 2025 in Washington, D.C.The presentation, titled Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline, is scheduled for Sunday, November 9, 2025, 9:00–9:15 AM EST in the session “Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology.” Presenting author: Aftab Ala, MBBS, M.D., FRCP, Ph.D. The abstract is on the conference website and presentation materials will be posted at www.monopartx.com on November 9, 2025.

5 months ago

#MNPR Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

www.stocktitan.net/news/MNPR/monopar-announ...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Trade Alerts, Thursday October 2, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Thu Oct 2nd - #IMRN #TSAS #SHLS #NVTS #MNPR #GIFI #DFLI #CAN #BTTC #CIGL #ANGX - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

$135 Million Raise: Biotech Monopar Therapeutics Prices Major Stock Offering with $35M Buyback Plan Clinical-stage biotech Monopar prices offering of 1M shares at $67.67 and 960K pre-funded warrants. Plans $35M stock repurchase from Tactic Pharma. Net proceeds of $100M for R&D and trials.

5 months ago

#MNPR Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/MNPR/monopar-therap...

0 0 0 0

Breakthrough: -0.367mg Daily Copper Reduction - Monopar's Drug Shows Promise for Wilson Disease Patients New analysis reveals ALXN1840 significantly improves copper balance in Wilson Disease patients, with -0.367mg daily difference at 15mg dose (p=0.005) and cumulative reduction of -6.08mg from baseline.

5 months ago

#MNPR Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

www.stocktitan.net/news/MNPR/monopar-announ...

0 0 0 0

6 months ago

NEWS: ( NASDAQ: #MNPR ) Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

0 0 0 0

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments Monopar Therapeutics (Nasdaq: MNPR) reported its Q2 2025 financial results and key developments. The company ended Q2 with $53.3 million in cash, expected to fund operations through December 2026. Notable developments include the transfer of ALXN1840's IND from Alexion Pharmaceuticals, with plans to submit an NDA in early 2026 for Wilson Disease treatment.The company reported a Q2 2025 net loss of $2.5 million ($0.35 per share), compared to $1.7 million ($0.49 per share) in Q2 2024. R&D expenses increased to $1.73 million, while G&A expenses rose to $1.50 million. Their MNPR-101 radiopharmaceutical program continues with active Phase 1 trials in Australia and an Expanded Access Program in the U.S.

7 months ago

#MNPR Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

www.stocktitan.net/news/MNPR/monopar-therap...

0 0 0 0

FDA Greenlights Expanded Access: New Treatment Hope for Breast, Pancreatic, and Colorectal Cancer Patients Novel radiopharmaceutical treatment now available for advanced cancers at premier therapy center. Multiple cancer types eligible. See treatment details.

9 months ago

#MNPR Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

www.stocktitan.net/news/MNPR/monopar-and-ed...

0 0 0 0

Monopar Therapeutics Added to Russell Indexes, Gains Access to $10.6T Benchmark Assets Clinical-stage biotech Monopar joins major Russell indexes June 27. Addition signals growth milestone, expanding institutional exposure. See market impact details.

9 months ago

#MNPR Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

www.stocktitan.net/news/MNPR/monopar-therap...

0 0 0 0

Syntaxx Research

@syntaxxresearch.bsky.social

9 months ago

#stocks #report #analysis #mgni #magnite #monopar #mnpr #appfolio #appf #research #blueskystocks #week1 #investment #money #economics #newyorkstockexchange #wallstreet #finance #stockmarket #advertising #pharma

0 0 0 0

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments Monopar Therapeutics (MNPR) reported Q1 2025 financial results and recent developments. The company presented promising long-term data for ALXN1840, a potential treatment for Wilson disease, showing sustained clinical benefits across 255 patients over 2.63 years with a favorable safety profile. The company plans to submit an NDA to FDA in early 2026. MNPR currently has two active Phase 1 trials for MNPR-101 radiopharmaceuticals in Australia. Financially, MNPR reported $54.6 million in cash and investments as of March 31, 2025, expected to fund operations through December 2026. Q1 2025 net loss was $2.6 million ($0.38/share) compared to $1.6 million ($0.51/share) in Q1 2024. R&D expenses increased to $1.64M from $966K, while G&A expenses rose to $1.58M from $757K year-over-year.

10 months ago

#MNPR Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

www.stocktitan.net/news/MNPR/monopar-therap...

0 0 0 0

10 months ago

Breaking News: ( NASDAQ: #MNPR ) Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

0 0 0 0

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 Monopar Therapeutics (Nasdaq: MNPR) presented late-breaker data at EASL 2025 on ALXN1840, their drug candidate for Wilson disease. The analysis pooled data from three clinical trials (n=255) for efficacy and included a fourth trial for safety analysis (n=266), with median treatment durations of 2.63 and 2.58 years respectively. Key findings showed sustained improvements in patient-reported and clinician-assessed symptoms (UWDRS), increased copper mobilization, better CGI-I scale results compared to standard care, and improvement in the New Wilson Index. The drug demonstrated strong safety with less than 5% of patients experiencing drug-related serious adverse events and no renal/urinary system SAEs. Patients reported higher convenience and effectiveness compared to standard treatment.

10 months ago

#MNPR Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

www.stocktitan.net/news/MNPR/monopar-presen...

0 0 0 0

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 Monopar Therapeutics announced that their ALXN1840 drug candidate for Wilson disease has been selected for a prestigious late-breaker presentation at the EASL International Liver Congress 2025 in Amsterdam. The presentation will focus on long-term efficacy and safety data of tiomolybdate choline (ALXN1840). The selection as a late-breaker abstract is significant, as these slots are reserved for the most recent and impactful research findings that could substantially influence the field. The presentation titled "Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline" will be delivered by Dr. Karl Heinz Weiss on May 7, 2025. The poster will be made available on Monopar's website the same day. This selection underscores the potential importance of the research, as late-breaker abstracts must meet strict criteria including presenting latest findings, demonstrating significant potential impact, and featuring prospective clinical studies.

10 months ago

#MNPR Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

www.stocktitan.net/news/MNPR/monopar-announ...

0 0 0 0

Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug $55M capital raise strengthens balance sheet as Monopar advances Wilson disease treatment ALXN1840 and two Phase 1 trials. See full pipeline progress.

11 months ago

#MNPR Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

www.stocktitan.net/news/MNPR/monopar-report...

0 0 0 0

Monopar Therapeutics Joins Elite Helix 51 Biomedical Hub to Accelerate Cancer Treatment Research Clinical-stage biotech Monopar Therapeutics expands R&D capabilities by joining Rosalind Franklin University's Helix 51 incubator to advance personalized radiopharmaceutical development.

1 year ago

#MNPR Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

www.stocktitan.net/news/MNPR/rosalind-frank...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #MNPR ) Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

#StockMarket #News

0 0 0 0

Monopar Therapeutics Raises $40M in Strategic Offering Backed by Major Healthcare Investors Biotech firm secures significant funding through combined public offering and private placement, with backing from RA Capital, Janus Henderson, and other key investors.

1 year ago

#MNPR Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

www.stocktitan.net/news/MNPR/monopar-therap...

0 0 0 0

Infamous CDP

@infamouscdp.bsky.social

1 year ago

Mount up. #regulators #MNPR

0 0 0 0

Monopar's Novel Radiopharmaceutical MNPR-101-Lu Achieves First-Ever Patient Dosing Milestone | MNPR Stock News Monopar Therapeutics reports successful first patient dosing of MNPR-101-Lu in metastatic pancreatic cancer, showing promising safety profile in compassionate use program.

1 year ago

#MNPR Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

#stocks #StockMarket #investing

www.stocktitan.net/news/MNPR/monopar-announ...

1 0 0 0

1 year ago

News; ( NASDAQ: #MNPR ) Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

#StockMarket #News

0 0 0 0

1 year ago

Breaking News: ( NASDAQ: #MNPR ) The MoBot Report

#StockMarket #News

1 0 0 0

1 year ago

NEWS: ( NASDAQ: #MNPR ) Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

#StockMarket #News

1 0 0 0

1 year ago

JUST IN: ( NASDAQ: #MNPR ) (MNPR) Trading Advice

#StockMarket #News

2 0 0 0

1 year ago

Just In: ( NASDAQ: #MNPR ) Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers

#StockMarket #News

1 0 0 0

1 year ago

Just In: ( NASDAQ: #MNPR ) Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #MNPR ) Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

#StockMarket #News

1 0 0 0